199 related articles for article (PubMed ID: 23757915)
1. [Antibody-drug conjugates: a new therapeutic class?].
Chofflon I; Dietrich PY; Thang NN
Rev Med Suisse; 2013 May; 9(387):1080-2, 1084-6. PubMed ID: 23757915
[TBL] [Abstract][Full Text] [Related]
2. Antibody-Drug Conjugates (ADCs) for Personalized Treatment of Solid Tumors: A Review.
Lambert JM; Morris CQ
Adv Ther; 2017 May; 34(5):1015-1035. PubMed ID: 28361465
[TBL] [Abstract][Full Text] [Related]
3. Antibody-drug conjugates in clinical trials for lymphoid malignancies and multiple myeloma.
Yu B; Liu D
J Hematol Oncol; 2019 Sep; 12(1):94. PubMed ID: 31500657
[TBL] [Abstract][Full Text] [Related]
4. Antibody-Drug Conjugates for Cancer Therapy.
Hafeez U; Parakh S; Gan HK; Scott AM
Molecules; 2020 Oct; 25(20):. PubMed ID: 33081383
[TBL] [Abstract][Full Text] [Related]
5. Drug-conjugated antibodies for the treatment of cancer.
Lambert JM
Br J Clin Pharmacol; 2013 Aug; 76(2):248-62. PubMed ID: 23173552
[TBL] [Abstract][Full Text] [Related]
6. Antibody-drug conjugates--an emerging class of cancer treatment.
Diamantis N; Banerji U
Br J Cancer; 2016 Feb; 114(4):362-7. PubMed ID: 26742008
[TBL] [Abstract][Full Text] [Related]
7. Antibody-drug conjugates for cancer therapy.
Thomas A; Teicher BA; Hassan R
Lancet Oncol; 2016 Jun; 17(6):e254-e262. PubMed ID: 27299281
[TBL] [Abstract][Full Text] [Related]
8. Stepping forward in antibody-drug conjugate development.
Jin Y; Schladetsch MA; Huang X; Balunas MJ; Wiemer AJ
Pharmacol Ther; 2022 Jan; 229():107917. PubMed ID: 34171334
[TBL] [Abstract][Full Text] [Related]
9. A review of the clinical efficacy of FDA-approved antibody‒drug conjugates in human cancers.
Liu K; Li M; Li Y; Li Y; Chen Z; Tang Y; Yang M; Deng G; Liu H
Mol Cancer; 2024 Mar; 23(1):62. PubMed ID: 38519953
[TBL] [Abstract][Full Text] [Related]
10. Predicting Response to Antibody Drug Conjugates: A Focus on Antigens' Targetability.
Ascione L; Crimini E; Trapani D; Marra A; Criscitiello C; Curigliano G
Oncologist; 2023 Nov; 28(11):944-960. PubMed ID: 37665782
[TBL] [Abstract][Full Text] [Related]
11. A Review of the Current FDA-Approved Antibody-Drug Conjugates: Landmark Clinical Trials and Indications.
Kesireddy M; Kothapalli SR; Gundepalli SG; Asif S
Pharmaceut Med; 2024 Jan; 38(1):39-54. PubMed ID: 38019416
[TBL] [Abstract][Full Text] [Related]
12. Fate of Antibody-Drug Conjugates in Cancer Cells.
Chalouni C; Doll S
J Exp Clin Cancer Res; 2018 Feb; 37(1):20. PubMed ID: 29409507
[TBL] [Abstract][Full Text] [Related]
13. Preclinical Characterization of Catabolic Pathways and Metabolism of ABBV-011, a Novel Calicheamicin-Based SEZ6-Targeting Antibody-Drug Conjugate.
Ladror D; Gu C; Tong V; Schammel A; Gavrilyuk J; Haight A; Sarvaiya H
Drug Metab Dispos; 2024 Jan; 52(2):135-142. PubMed ID: 38050039
[TBL] [Abstract][Full Text] [Related]
14. A pharmacovigilance study on drug-induced liver injury associated with antibody-drug conjugates (ADCs) based on the food and drug administration adverse event reporting system.
Sun C; Yang X; Tang L; Chen J
Expert Opin Drug Saf; 2023 Oct; ():1-12. PubMed ID: 37898875
[TBL] [Abstract][Full Text] [Related]
15. The ever-expanding landscape of antibody-drug conjugates (ADCs) in solid tumors: A systematic review.
Filis P; Zerdes I; Soumala T; Matikas A; Foukakis T
Crit Rev Oncol Hematol; 2023 Dec; 192():104189. PubMed ID: 37866413
[TBL] [Abstract][Full Text] [Related]
16. Antibody-drug conjugates in oncology: insights into Current challenges.
Al Meslamani AZ; Bostanudin MF
Expert Opin Biol Ther; 2023; 23(11):1035-1038. PubMed ID: 37883244
[No Abstract] [Full Text] [Related]
17. Cancer-targeting antibody-drug conjugates drive dealmaking frenzy.
Senior M
Nat Biotechnol; 2024 Mar; 42(3):362-366. PubMed ID: 38409588
[No Abstract] [Full Text] [Related]
18. Antibody-Drug Conjugates and Ocular Toxicity.
Jaffry M; Choudhry H; Aftab OM; Dastjerdi MH
J Ocul Pharmacol Ther; 2023 Dec; 39(10):675-691. PubMed ID: 37615544
[TBL] [Abstract][Full Text] [Related]
19. Peptide-drug conjugates: A new paradigm for targeted cancer therapy.
Wang M; Liu J; Xia M; Yin L; Zhang L; Liu X; Cheng Y
Eur J Med Chem; 2024 Feb; 265():116119. PubMed ID: 38194773
[TBL] [Abstract][Full Text] [Related]
20. How antibody-drug conjugates aim to take down cancer.
Plackett B
Nature; 2024 May; 629(8014):S2-S3. PubMed ID: 38811702
[No Abstract] [Full Text] [Related]
[Next] [New Search]